The oxylipin analog CS585 prevents platelet activation and thrombosis through activation of the prostacyclin receptorLivia Stanger, Michael Holinstat, Devin Gilmore et al.|Blood|2023Cited by 18
HDAC Inhibitor CS014 Attenuates Thrombosis Alone and in Combination with Rivaroxaban without Increased Risk of BleedingLivia Stanger, Björn Dahlöf, Sylviane Lambert et al.|Blood|2023Cited by 1
Superiority of CS585 as a selective prostacyclin receptor agonist in prevention of thrombosisLivia Stanger, Michael Holinstat, Sylviane Lambert et al.|European Heart Journal|2023Cited by 0
CS585 Demonstrates Favorable Selectivity and Sustained <i>In Vivo</i> Action in Preventing Platelet Activation and Thrombosis Compared to Existing IP Receptor AgonistsLivia Stanger, Michael Holinstat, Niklas Bergh et al.|Blood|2023Cited by 0